viernes, 8 de junio de 2018

Fibromyalgia Device: Hummingbirds Hum - Ivanhoe Broadcast News, Inc.

Fibromyalgia Device: Hummingbirds Hum - Ivanhoe Broadcast News, Inc.

Marketing




LOUIS, Mo. (Ivanhoe Newswire) — Chronic itch affects up to 15 percent of the population and for many patients, it can be a life-changing condition because the urge to itch is always there, disrupting everyday activities and making it nearly impossible to sleep well. Now, for the first time, doctors have found a drug that could finally offer relief.




MIAMI, Fla. (Ivanhoe Newswire) — Fibromyalgia is often called a mystery illness that causes debilitating pain and fatigue. Most patients take pills to help relieve symptoms. Now, new technology is offering help without the side effects of medication.




TAMPA, Fla. (Ivanhoe Newswire) — The thyroid is a small gland in the front of your neck and it happens to be a favorite target for cancer. According to the American Cancer Society, thyroid cancer cases have tripled in the last three decades. The good news: it’s treatable. There are symptoms you need to watch out for … especially if you’re a woman.




SAN DIEGO, Calif. (Ivanhoe Newswire) — The CDC estimates that one in 68 children in the U.S. are on the autism spectrum. Right now, there are no FDA approved treatments for the disorder or its symptoms, which can include difficulty with social skills, communication and repetitive behavior. That’s why results of a small clinical trial in San Diego have grabbed the attention of researchers and families.




BALTIMORE, Md. (Ivanhoe Newswire) — It’s a condition that causes the body’s immune system to turn against its own muscles, making it difficult to walk or lift heavy things. Inclusion-body myositis is often misdiagnosed or dismissed as a normal part of aging.








Doctor's In-depth Interview of the week
 
COPD: Harmonicas for Better Health? 
 



Quote of the week:

“The entire cosmos can sing to us with the voices of a wild flower.” 

— Thich Nhat Hanh






Website Information: webdoctor@ivanhoe.com

Content Licensing: jcherry@ivanhoe.com

No hay comentarios:

Publicar un comentario